文献速递免疫规划传染病防控与疫情报告

17DD黄热病疫苗两剂接种者免疫持久性

Duration of immunity in recipients of two doses of 17DD yellow fever vaccine.
PubMed 文献 · Vaccine · 2019-06-03

横断面研究评估323名接种过至少两剂17DD黄热病疫苗的成人免疫状态。末次接种后1-5年、6-9年及10年以上组血清阳性率分别为90%、86%和86%,均低于参考组(接种后30-45天)的100%。结果支持维持黄热病疫苗加强剂以保持保护性抗体水平。

要点

  • 两剂接种后血清阳性率随时间下降,10年以上组为86%。
  • 参考组(第二剂后30-45天)血清阳性率为100%。
  • 研究支持需要加强剂以维持保护性抗体水平。

核心结论

  • 两剂17DD黄热病疫苗接种后,血清阳性率随时间推移而下降,支持需要加强剂维持保护性抗体水平。
  • 少数个体可能需要超过两剂,但应优先为所有易感者进行初种。

研究设计与样本

  • 横断面研究,共纳入323名曾接种至少两剂17DD黄热病疫苗的成人。
  • 按末次接种后时间分组:30-45天(参考组)、1-5年、6-9年、10年及以上,以及接种三剂及以上组。
  • 通过疫苗接种卡核实和访谈,采血检测黄热病中和抗体滴度及登革IgG。

主要发现

  • 参考组(n=99)在第二剂前69%为血清阳性。
  • 再接种后血清阳性率(95%CI):参考组100%(96-100%),1-5年组90%(83-95%,n=109),6-9年组86%(77-92%,n=92),10年及以上组86%(57-98%,n=14)。
  • 仅9名接种超过两剂者符合研究条件,其中8人血清阳性。
  • 社会人口学变量、接种年龄和既往登革感染未混淆血清阳性与末次接种后时间的关联。

关键数值与推荐

  • 血清阳性定义为中和抗体滴度≥1:50。
  • 参考组(第二剂后30-45天)血清阳性率100%(95%CI 96-100%)。
  • 1-5年组血清阳性率90%(95%CI 83-95%)。
  • 6-9年组血清阳性率86%(95%CI 77-92%)。
  • 10年及以上组血清阳性率86%(95%CI 57-98%)。

临床怎么用

  • 应优先为所有易感者进行黄热病疫苗初种。
  • 对于已接种两剂者,可考虑加强剂以维持保护性抗体水平。
  • 少数个体可能需要超过两剂,但需结合个体情况评估。

局限性

  • 横断面设计无法确定个体抗体水平的动态变化。
  • 10年及以上组和接种超过两剂组样本量小。
  • 未报告GMT的具体数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antibody levels following yellow fever vaccination (YFV) decrease considerably with time, leaving a substantial proportion of single-dose recipients seronegative after 10 years. Little is known about the persistence of immunity after two or more doses of the vaccine. This study was designed to verify the current immune status of adults who had received two or more doses of YFV. A cross-sectional study assessed the immune status for yellow fever according to time since the latest YFV: second dose at 30-45 days (reference group), 1-5 years, 6-9 years and 10 years or more; and three or more doses. Volunteers had their vaccination cards checked and were interviewed before having a blood sample drawn for titration of neutralizing YF antibodies, and being tested for dengue IgG. The proportion seropositive (titer ≥ 1:50) and the geometric mean titers (GMT) were compared among the subgroups of time since the latest YFV. Participants (n = 323) were predominantly female (80.5%) and had a median age of 34 years (range 18-76). In the reference group (n = 99), 69% were seropositive before the second dose. After revaccination, the proportions seropositive (95% C.I.) were 100% (96-100%) in the reference subgroup, 90% (83-95%) in the 1-5 year subgroup (n = 109), 86% (77-92%) in the 6-9 year subgroup (n = 92) and 86% (57-98%) in the 10+ years subgroup (n = 14). Only 9 participants with more than 2 previous doses of YFV were eligible for the study, and 8 of them were seropositive. Sociodemographic variables, age at vaccination and previous dengue infection did not confound the association of seropositivity to time since the last YFV. The results support the need of booster doses of the YFV to maintain antibody levels consistent with protection, and indicate that a small proportion of individuals may need more than two doses, provided that priority is given to primovaccination of all susceptibles.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Duration of immunity in recipients of two doses of 17DD yellow fever vaccine. Vaccine. 2019. PMID: 31171393. doi:10.1016/j.vaccine.2019.05.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。